KAYA

Kaya financials

Market cap
₹504 Cr
Calls analysed
2
Latest concall · Q1 FY26 · call held 06 Aug 2025

Kaya Ltd Q1 FY26

Revenue from Operations ₹52.8 cr +1%

What went well

  • Clinic business registered a 7% collection growth over Q1 FY25.
  • Clinic product business witnessed an 11% growth versus Q1 FY25.
  • Services business registered a collection growth of 6% over Q1 FY25.

What to watch

  • Standalone loss after tax and other comprehensive income was negative ₹14.2 crores in Q1 FY26, compared to a profit of ₹6.4 crores in Q1 FY25 (which included a one-time gain of ₹15.8 crores).
  • Employee benefit cost rose to over ₹16.24 lakhs this quarter, driven by increments, productivity incentives, and new clinic contests.
Read the full call →

What Kaya Ltd does

Kaya Limited runs a pan-India chain of dermatology clinics offering personalised skin, hair and body services such as anti-ageing treatment, acne and scar therapy, laser hair reduction, brightening and pigmentation treatment and body contouring, delivered by qualified dermatologists and beauty professionals. It also formulates and sells a Kaya-branded range of skin-care, hair-care and nutraceutical products (including the Kaya Nutra+ line) through its clinics. The company earns revenue from clinic service fees for treatments and from sale of its proprietary product portfolio.

Segments

  • Skin Care
  • Hair Care
  • Body Care
  • Nutraceuticals
Clinics
75+
Dermatologists
100+
Cities
25+
States
15
Product portfolio
75+
Cumulative clients served
35+ lakh (~3.5 million) beautified
Founded 2003Headquarters Mumbai, Maharashtra, India Company website

Guidance record · Q1 FY26

what the last two calls moved 5 tracked 0 delivered 1 missed 4 open
  • Clinic Renovation Program went quiet said Q4 FY25 Promised: Program will continue into FY26 Q1 FY26: No update provided on renovations; focus shifted entirely to new machines and new clinics.
  • Annual Profitability Improvement delayed said Q4 FY25 Promised: INR 18 crores annual improvement post rights issue (debt retirement) Q1 FY26: Fundraising strategy shifted to preferential allotment first; rights issue delayed, pushing back debt retirement timeline.
  • New Clinic Additions on track said Q4 FY25 Promised: 7 clinics signed for FY26 Q1 FY26: Launched 2 in Q1, targeting 8 operational by Sep/Oct 2025.

All 5 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q4 FY26: revenue up 1.8%, net profit down 300.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue52 53 58 55 53 +2%54 +2%60 +3%56 +2%
EBITDA6 6 5 2 4 −33%-3 −150%-11 −320%-13 −750%
Net profit103 -16 4 -7 -14 −114%-19 −19%-36 −1000%-28 −300%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −18.1% 1Y

₹300₹400₹500Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹405 on 10 Sept 2025 → ₹331.7. High ₹482.45 (23 Sept 2025), low ₹227.1 (3 Jun 2026).

Financials, as filed

Revenue fell 16.1% a year over 3 years, FY23 to FY26. Operating margin narrowed to -10.3%.

Year endingFY23FY24FY25FY26
Revenue₹377 Cr₹217 Cr₹218 Cr₹223 Cr
Operating profit₹-25 Cr₹-38 Cr₹19 Cr₹-23 Cr
Operating margin-6.6%-17.5%8.7%-10.3%
Interest₹36 Cr₹26 Cr₹31 Cr₹35 Cr
Depreciation₹60 Cr₹37 Cr₹37 Cr₹45 Cr
Net profit₹-117 Cr₹-130 Cr₹84 Cr₹-97 Cr
Net margin-31.0%-59.9%38.5%-43.5%
Cash from operations₹63 Cr₹39 Cr₹1 Cr₹21 Cr
Free cash flow₹39 Cr₹5 Cr₹-12 Cr₹-17 Cr
ROCE-44.0%-62.0%-16.0%-46.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹13 Cr₹13 Cr₹13 Cr₹13 Cr₹15 Cr₹15 Cr
Reserves₹41 Cr₹-15 Cr₹-117 Cr₹-240 Cr₹-108 Cr₹-168 Cr
Borrowings₹160 Cr₹204 Cr₹249 Cr₹301 Cr₹278 Cr₹296 Cr
Other liabilities₹153 Cr₹159 Cr₹225 Cr₹221 Cr₹123 Cr₹135 Cr
Total liabilities₹368 Cr₹361 Cr₹370 Cr₹295 Cr₹308 Cr₹278 Cr
Fixed assets₹279 Cr₹240 Cr₹217 Cr₹174 Cr₹184 Cr₹193 Cr
Capital work in progress₹1 Cr₹2 Cr₹2 Cr₹1 Cr₹0 Cr₹0 Cr
Investments₹11 Cr₹26 Cr₹21 Cr₹29 Cr₹58 Cr₹39 Cr
Other assets₹77 Cr₹93 Cr₹130 Cr₹91 Cr₹66 Cr₹46 Cr
Total assets₹368 Cr₹361 Cr₹370 Cr₹295 Cr₹308 Cr₹278 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters trimmed −8.21 pp while the public added +7.56 pp. The shareholder count shrank 8% to 18,043.

Promoters
51.4%
FIIs
0.7%
DIIs
3.0%
Public
44.9%

Since Jun 2025

  • Promoters −8.21 pp
  • Public +7.56 pp
  • DIIs +0.90 pp

How it drifted, 12 quarters

Over this window promoters fell from 59.9% to 51.4% — −8.5 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 59.9%, FIIs 0.8%, DIIs 1.3%, Public 37.9%.Dec '23: Promoters 59.9%, FIIs 0.7%, DIIs 1.3%, Public 38.0%.Mar '24: Promoters 59.8%, FIIs 0.7%, DIIs 2.0%, Public 37.5%.Jun '24: Promoters 59.8%, FIIs 1.3%, DIIs 3.5%, Public 35.4%.Sep '24: Promoters 59.6%, FIIs 1.3%, DIIs 3.6%, Public 35.5%.Dec '24: Promoters 59.6%, FIIs 1.3%, DIIs 3.4%, Public 35.7%.Mar '25: Promoters 59.6%, FIIs 1.5%, DIIs 1.7%, Public 37.2%.Jun '25: Promoters 59.6%, FIIs 0.9%, DIIs 2.1%, Public 37.3%.Sep '25: Promoters 51.4%, FIIs 0.6%, DIIs 2.5%, Public 45.4%.Dec '25: Promoters 51.4%, FIIs 0.6%, DIIs 2.8%, Public 45.1%.Mar '26: Promoters 51.4%, FIIs 0.7%, DIIs 3.0%, Public 44.9%.Jun '26: Promoters 51.4%, FIIs 0.7%, DIIs 3.0%, Public 44.9%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Kaya Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

All earnings calls (2)

Read the Q1 FY26 call →